On September 11, 2019 MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), reported that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O’Brien, JD/MBA, Vice President and Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019 at 10:30 am at the Sofitel Hotel in New York City (Press release, MediciNova, SEP 11, 2019, View Source [SID1234539470]). Management will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through Ladenburg Thalmann.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 11, 2019 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, reported that clinical data on its investigational anti-PD-1 antibody tislelizumab, its investigational BTK inhibitor zanubrutinib, and its investigational PARP inhibitor pamiparib, will be presented in seven oral presentations and four poster presentations at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO), taking place September 18-22, 2019 in Xiamen, China (Press release, BeiGene, SEP 11, 2019, View Source [SID1234539469]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentations:

Title: Tislelizumab in Chinese Patients with Non-Small Cell Lung
Cancer (NSCLC) and Nasopharyngeal Carcinoma (NPC)
Session: Lung Cancer Session 1
Date: Thursday, September 19
Time: 11:20 – 11:25
Location Auditorium, Level 1
Presenter Qing Zhou, M.D., Ph.D., Guangdong Provincial People’s Hospital

Title: Tislelizumab for Relapsed/Refractory Classical Hodgkin
Lymphoma: Updated Follow-up Efficacy and Safety Results
from a Phase 2 Study
Session: Innovative Drug Clinical Data Session 1
Date: Thursday, September 19
Time: 14:30 – 14:40
Location Strait Hall, Level 2
Presenter: Yuqin Song, M.D., Ph.D., Beijing Cancer Hospital

Title: Tislelizumab in Chinese Patients with Melanoma, Urothelial
Carcinoma (UC), and Renal Cell Carcinoma (RCC)
Session: Kidney Cancer Session 4
Date: Thursday, September 19
Time: 16:35 – 16:40
Location Conference Room 2A, Level 2
Presenter: Lili Mao, M.D., Ph.D. Beijing Cancer Hospital

Title: Tislelizumab in Chinese Patients with Esophageal Cancer
(EC), Gastric Cancer (GC), Hepatocellular Carcinoma (HCC),
and Microsatellite Instability-High/Mismatch Repair Deficient
(MSI-H/dMMR) Tumors
Session: Advanced Gastric Cancer Session 3
Date: Friday, September 20
Time: 11:24 – 11:36
Location Banquet Hall 1, Level 2
Presenter: Lin Shen, M.D., Ph.D., Beijing Cancer Hospital

Title: Safety and Efficacy in Patients with Long-Term Exposure
(LTE) to Tislelizumab, an Investigational Anti-PD-1 Antibody,
in a First-in-Human Phase 1 Study
Session: Immuno-Oncology Session 3
Date: Friday, September 20
Time: 11:54 – 12:00
Location Hall 1G, Level 1
Presenter Chia-Jui Yen, M.D., Ph.D., National Cheng Kung University Hospital

Title: Tislelizumab Plus Chemotherapy as First-Line Treatment for
Chinese Patients with Lung Cancer
Session: Lung Cancer Session 3
Date: Saturday, September 21
Time: 11:38 – 11:44
Location Auditorium, Level 1
Presenter: Zhijie Wang, M.D., Ph.D., Cancer Hospital, Chinese Academy of Medical Sciences

Title: Tislelizumab in Combination with Chemotherapy as
Treatment for Chinese Patients with Esophageal Squamous
Cell Carcinoma (ESCC)
Session: Innovative Drug Clinical Data Session 1
Date: Saturday, September 21
Time: 14:30 – 14:40
Location Banquet Hall 2, Level 2
Presenter: Ru Jia, M.D., The Fifth Medical Center, General Hospital of the People’s Liberation Army

Poster Presentations:

Title: Dose Escalation of Pamiparib in Chinese Patients with High-
Grade Non-Mucinous Ovarian Cancer (HGOC) or Advanced
Triple-Negative Breast Cancer (TNBC)
Board #: P-36
Date: Thursday, September 19
Time: Afternoon
Location: Strait Hall Poster Area, Level 2
Presenter: Xiyan Mu, M.D., BeiGene

Title: Zanubrutinib for Patients with Relapsed or Refractory
Chronic Lymphocytic Leukemia or Small Lymphocytic
Lymphoma
Board #: P-45
Date: Friday, September 20
Time: Morning
Location: Strait Hall Poster Area, Level 2
Presenter: Meng Ji, M.D., BeiGene

Title: Zanubrutinib, a Highly Specific BTK Inhibitor in Chinese
Patients with Relapsed/Refractory B-cell Malignancies:
Follow-up Report of a Phase 1 Trial in China
Board #: P-46
Date: Friday, September 20
Time: Morning
Location: Strait Hall Poster Area, Level 2
Presenter: Chenmu Du, M.D., BeiGene

Title: The molecular binding mechanism of tislelizumab, an
investigational anti-PD-1 antibody, is differentiated from
pembrolizumab and nivolumab
Board #: P-60
Date: Friday, September 20
Time: Morning
Location: Strait Hall Poster Area, Level 2
Presenter: Ye Liu, Ph.D., BeiGene

On September 11, 2019 Biogen Inc. (Nasdaq:BIIB) reported it will report third quarter 2019 financial results Tuesday, October 22, 2019, before the financial markets open (Press release, Biogen, SEP 11, 2019, View Source [SID1234539468]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the release of the financials, the Company will host a live webcast with Biogen management from 8:00-9:00 am ET. To access the live webcast, please go to the investors section of Biogen’s website at View Source Following the live webcast, an archived version of the call will be available on the website.

On September 11, 2019 Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, in particular against rare or resistant cancers, reported that its management team will attend the following key investor and scientific conferences in the coming months (Press release, Onxeo, SEP 11, 2019, View Source [SID1234539466]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investir Day
October 15, 2019, Paris, France

A new event providing shareholders and retail investors with the opportunity to meet and discuss with executives of listed companies. A masterclass session by Judith Greciet, CEO of Onxeo, is scheduled during the event.

The Galien Medstartup 2019
October 24, 2019, in New York, NYC, United-States

The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Its vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.

AACR-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper)
October 26-30, 2019, in Boston, MA, United-States

The premier international meeting featuring novel cancer therapeutics organized by the American Association for Cancer Research (AACR) (Free AACR Whitepaper), the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC).

Direct Dirigeants event with Les Echos – Investir
November 6, 2019, in Paris, France

Presentation by Judith Greciet, CEO of Onxeo, to individual investors and shareholders.

2nd Annual DNA Damage Response Therapeutics Summit
January 29-31, 2019, in Boston, MA, United-States

The Summit brings together the leading pharma and biotech companies accelerating the development of DNA repair pathway inhibitors, to optimize drug discovery, broaden patient population and generate greater efficacy.

190911_PR_Onxeo_Conferences H2 2019

On September 11, 2019 Atomwise Inc. ("Atomwise"), the leader in artificial intelligence (AI) for drug discovery, reported a collaboration with Hansoh Pharmaceutical Group Company Limited ("Hansoh Pharma"), a leading biopharmaceutical company in China, to design and discover potential drug candidates for up to eleven undisclosed target proteins in multiple therapeutic areas (Press release, Atomwise, SEP 11, 2019, View Source [SID1234539463]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"There is exciting science happening throughout Asia, and enormous potential for leadership in innovative drug discovery," said Dr. Abraham Heifets, CEO of Atomwise. "I am delighted to announce that Hansoh Pharma is our first partner in Asia. Hansoh Pharma is committed to innovation and shares our mission for global impact on patient health," he added.

Scientific teams from Atomwise and Hansoh Pharma will collaborate closely on the programs. The combination of Atomwise’s AI technology and medicinal chemistry and protein structure expertise, and Hansoh Pharma’s fully integrated research and development, manufacturing and commercial capabilities has the potential to dramatically increase success and compress timelines for drug discovery and clinical development.

Under the terms of the collaboration, Atomwise will receive undisclosed technology access fees, option exercise fees, royalties, and income based on sublicensing or sale of assets created under the collaboration. Based on historical average revenues for small molecule drugs, the total potential value of the deal to Atomwise with success in all projects could reach US$1.5 billion.